Insider buying last 90 days
No open-market insider purchases were filed for TAK in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every TAK insider filing, plotted on the chart in Gekko.Open TAK in Gekko
Takeda Pharmaceutical (TAK) Stock Analysis & Forecast
Nov 4 close
$21.06+0.31 (+1.5%)
Gekko Brief
AI summaryNov 4 closeThis week Takeda's news flow centered on regulatory and product momentum alongside its latest quarter. Zasocitinib, a computationally designed psoriasis pill, is nearing FDA approval in early 2027, while orexin received FDA approval as the first agonist drug for Type 1 narcolepsy. Separately, Takeda reported second-quarter adjusted earnings of 48 cents per share against a consensus of 31 cents, with H1 FY2026 core revenue down 1% at CER but core operating profit up 0.7%, aided by transformation savings; management raised its outlook despite a generic overhang. Analyst commentary was mixed, with one note reiterating a Hold on cash-flow concerns even as average price targets were raised toward $21.19.
TAK closed at $21.06, up 1.5%, sitting above both its 50-day ($19.00) and 200-day ($17.62) moving averages, with the shorter average above the longer one. The GekkoIndex reads 46.7, placing it in the Neutral zone, down slightly over the past five readings. Gekko Fair Value stands at $25.66, leaving the current price about 17.9% below that mark.
The next earnings date falls on 28 January 2027, 84 days out and beyond a typical 20-trading-day holding window. No insider, Congress or unusual options activity appears in the recent windows. Seasonally, the next 20 trading days have averaged a 1.9% gain over 5 years, rising in 3 of them, a pattern worth noting alongside the gap to Gekko Fair Value.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
Takeda Pharmaceutical price vs fair value
Close $21.06200-day averageGekko Fair Value $25.66
Takeda Pharmaceutical quick facts
- Market cap
- $67.28B
- P/E ratio
- 298.1
- Forward P/E
- 12.8
- EPS, TTM
- $0.07
- Revenue, TTM
- $4.69T
- Profit margin
- 0.9%
- Dividend yield
- 2.95%
- Beta
- 0.08
- Volume
- 2.97M avg 2.92M
- 1-year return
- +56.9%
- Typical daily move
- ±2%
- Typical 20-day move
- ±3.9%
- 50-day average
- $19.00
- 200-day average
- $17.62
- Next earnings
- Jan 28 before open
- Shares outstanding
- 3.19B
Takeda Pharmaceutical swing-trade checklist
Takeda Pharmaceutical scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
- Trendsupportive
Above 50 and 200-day
Close $21.06 is above the 50-day ($19.00) and 200-day ($17.62) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
46.7, Neutral
Reading 46.7 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
17.9% below
Price is 17.9% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 84 days
Next report Jan 28, 2027, 84 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+1.9% on average
From this point in the calendar, the next 20 trading days averaged +1.9% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Takeda Pharmaceutical stock chart and price history
Takeda Pharmaceutical closed at $21.06 on Nov 4, 2026, +56.9% over the past year, inside a 52-week range of $13.50 to $21.22.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +16.4%
- 3 months
- +23.7%
- 6 months
- +26.0%
- 1 year
- +56.9%
The full TAK chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open TAK in Gekko
Follow Takeda Pharmaceutical through every session
Put TAK on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track TAK in GekkoFree for 7 days. No credit card required.
About Takeda Pharmaceutical
Takeda Pharmaceutical works across the full life cycle of medicines, from early discovery through development, manufacturing, sale and licensing to other firms. It sells treatments aimed at digestive conditions, rare diseases, blood-plasma therapies, cancer and neurological disorders, reaching patients in Japan, the United States, Europe, Canada, Latin America, Russia and other markets in Asia and beyond. Its products are sold under a long list of brand names, including Entyvio, Takecab, Dexilant, Advate, Adcetris, Vyvanse and Trintellix, among many others.
Beyond its own pipeline, Takeda builds its business through a network of outside agreements. It licenses products out to companies such as Neurocrine Biosciences, and it brings in research or licensed compounds through deals with groups like MD Anderson Cancer Center, Arrowhead Pharmaceuticals, Ovid Therapeutics and Evox Therapeutics. It also runs research partnerships with firms including Crescendo Biologics, Poseida Therapeutics, Selecta Biosciences, Skyhawk Therapeutics and Evotec, among several others.
The company was founded in 1781 and is headquartered in Tokyo, Japan. Its shares trade under the ticker TAK.
- Sector
- Health technology
- Website
- takeda.com
Takeda Pharmaceutical GekkoIndex: the smart money zone
Takeda Pharmaceutical’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 46.7, in the Neutral zone, down 1.2 points over five sessions.
46.7Neutral
Down 1.2 points over five sessions.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 44 | +0.9% | +1.0% | ||
| Accumulation | 208 | −0.1% | +0.2% | ||
| Neutral (current zone) | 362 | +0.5% | +1.6% | ||
| Distribution | 36 | +0.5% | +4.5% | ||
| Selling | 0 | Not available | |||
Average TAK share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.0% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the TAK price, zone by zone.Track TAK in Gekko
Is Takeda Pharmaceutical stock overvalued? Gekko Fair Value
Takeda Pharmaceutical trades 17.9% below Gekko Fair Value of $25.66, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Takeda Pharmaceutical shares are worth, recalculated every trading day.
$25.66
Gekko Fair Value, Nov 4, 2026
17.9% Undervalued
At the end of Aug 2026 the price was 28.1% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open TAK in Gekko
Takeda Pharmaceutical insider and Congress trading
No open-market insider purchases were filed for Takeda Pharmaceutical, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in TAK were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for TAK, plotted on the chart in Gekko.Open TAK in Gekko
Takeda Pharmaceutical earnings: next date and track record
Takeda Pharmaceutical reports on Jan 28, 2027, before the open (84 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Jan 28, 2027
Expected before the open, 84 days away
- EPS estimate
- $0.28
- Revenue estimate
- $7.72B
3 of 8reports beat the EPS estimate
±3%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Oct 29, 2026 AI summary
- What they said
- Takeda reported H1 FY2026 core revenue of JPY 2.4 trillion (-1% CER), core operating profit of JPY 710.6 billion (+0.7% CER), and core EPS of JPY 308 (-1.2% CER). Key launches include ORZEYFUL for narcolepsy in Japan/China (U.S. launch expected November), MIMRYLO for polycythemia vera in the U.S., and ELAHERE approval in Japan. FDA accepted zasocitinib NDA under priority review. Phase III TAK-921 met dual primary endpoints in gastric cancer.
- Guidance
- Management reaffirmed full year FY2026 forecast and guidance. Transformation program savings are offsetting launch investments to protect core operating profit. TAK-921 regulatory filing in Japan planned for FY2027.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 29, 2026 | $0.39 est $0.14 | $7.55B est $7.34B | +3.8% |
| Jul 30, 2026 | $0.23 est $0.17 | $7.66B est $7.13B | −3.7% |
| May 13, 2026 | −$0.05 est $0.21 | $6.92B est $7.14B | +1.3% |
| Jan 29, 2026 | $0.48 est $0.55 | $7.73B est $7.54B | +3.2% |
| Oct 30, 2025 | $0.44 est $0.44 | $7.42B est $7.48B | −2.4% |
| Jul 30, 2025 | $0.52 est $0.47 | $7.64B est $7.95B | −4.2% |
| May 8, 2025 | −$0.23 est −$0.17 | — | −4.6% |
| Jan 30, 2025 | $0.05 est $0.63 | $7.28B est $7.06B | +0.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Takeda Pharmaceutical stock forecast and analyst price targets
Analysts’ average 12-month price target for Takeda Pharmaceutical is $23.02, +9.3% from the last close, from 1 firm rating the stock in the last 90 days.
$23.02consensus 12-month target, +9.3% from the last close
Each firm’s latest rating in the last 90 days: 1 firm.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 14 | Bank of America Securities | $43.92 | +108.5% |
| Aug 13 | Bank of America Securities | $42.65 | +102.5% |
| Aug 6 | Bank of America Securities | — | — |
+1.6%average 20-day move after past Neutral readings
+1.9%average move over the next 20 trading days in the last 5 years
±2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Takeda Pharmaceutical seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, Takeda Pharmaceutical averaged +1.9% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.4% | 2 of 5 |
| Next 10 trading days | +0.9% | 2 of 5 |
| Next 15 trading days | +1.5% | 3 of 5 |
| Next 20 trading days | +1.9% | 3 of 5 |
| Next 30 trading days | +1.8% | 2 of 5 |
For scale, TAK’s typical 20-trading-day move in either direction is about 3.9%.
Takeda Pharmaceutical market cap and key statistics
Takeda Pharmaceutical’s market cap is $67.28B, with a P/E ratio of 298.1 and revenue of $4.69T over the last twelve months.
Valuation
- Market cap
- $67.28B
- P/E ratio
- 298.1
- Forward P/E
- 12.8
- EPS, TTM
- $0.07
- Gekko Fair Value
- $25.66
Trading
- Volume
- 2.97M
- Avg volume, 20 days
- 2.92M
- 52-week high
- $21.22
- 52-week low
- $13.50
- Shares outstanding
- 3.19B
Financials
- Revenue, TTM
- $4.69T
- Profit margin
- 0.9%
- Return on equity
- 0.6%
- Quarterly earnings growth, YoY
- −9.8%
Risk and income
- Beta
- 0.08
- Typical daily move
- ±2%
- Typical 20-day move
- ±3.9%
- Dividend yield
- 2.95%
Takeda Pharmaceutical stock news this week
Coverage of Takeda Pharmaceutical this week reads positive: 11 positive, 0 neutral and 0 negative headlines.
- Takeda’s AI-Crafted Pill Is Up for FDA Approval. It’s Not a CureBusiness Model Analyst, Nov 4
- Takeda Pharmaceutical Co. $TAK Shares Sold by Heritage Investors Management CorpDefense World, Nov 3
- Takeda Pharmaceutical's Orexin Gains FDA ApprovalLabroots, Nov 2
- Takeda Pharmaceutical Company Limited Stock 12‑Month Price Target Raised to $21.19, Implies 6% UpsideTradingView, Oct 31
- Takeda Pharmaceutical Company Limited Stock 12‑Month Price Target Raised to $21.12, Implies 6% UpsideTradingView, Oct 30
- Takeda Pharmaceutical's Earnings Growth Has Yet To Translate To Higher Cash FlowSeeking Alpha, Oct 30
Takeda Pharmaceutical stock FAQ
What is Takeda Pharmaceutical’s market cap?
Takeda Pharmaceutical’s market cap is $67.28B at the Nov 4, 2026 close of $21.06, with 3.19B shares outstanding. The shares trade on a P/E ratio of 298.1.
What is the Takeda Pharmaceutical stock forecast?
The consensus analyst 12-month price target for Takeda Pharmaceutical is $23.02, +9.3% from the last close. Of the 1 firm that rated the stock in the last 90 days, 1 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Takeda Pharmaceutical stock overvalued or undervalued?
On Gekko’s estimate Takeda Pharmaceutical is undervalued: the Nov 4, 2026 close of $21.06 is 17.9% below Gekko Fair Value of $25.66. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Takeda Pharmaceutical report earnings next?
Takeda Pharmaceutical is expected to report on Jan 28, 2027, before the market opens (84 days away). Analysts expect earnings of $0.28 per share on revenue of $7.72B. Takeda Pharmaceutical beat the earnings estimate in 3 of its last 8 reports, moving 3% on average across the report.
What is Takeda Pharmaceutical’s 52-week high and low?
Takeda Pharmaceutical’s 52-week high is $21.22 and its 52-week low is $13.50; it closed at $21.06 on Nov 4, 2026, +56.9% over the past year.
Is Takeda Pharmaceutical stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (trend, fair value, earnings risk and seasonality), 1 as mixed (gekkoindex). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Takeda Pharmaceutical the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.